180 related articles for article (PubMed ID: 11346305)
1. Antibody to HIV-1 Tat protein, a key molecule in HIV-1 pathogenesis. A brief review.
Re MC; Gibellini D; Vitone F; La Placa M
New Microbiol; 2001 Apr; 24(2):197-205. PubMed ID: 11346305
[TBL] [Abstract][Full Text] [Related]
2. The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.
Rodriguez SK; Sarr AD; Olorunnipa O; Popper SJ; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
J Infect Dis; 2006 Sep; 194(6):760-3. PubMed ID: 16941341
[TBL] [Abstract][Full Text] [Related]
3. Relationships between the presence of anti-Tat antibody, DNA and RNA viral load.
Re MC; Gibellini D; Furlini G; Vignoli M; Vitone F; Bon I; La Placa M
New Microbiol; 2001 Jul; 24(3):207-15. PubMed ID: 11497076
[TBL] [Abstract][Full Text] [Related]
4. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
[TBL] [Abstract][Full Text] [Related]
5. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
6. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates.
Mascarell L; Bauche C; Fayolle C; Diop OM; Dupuy M; Nougarede N; Perraut R; Ladant D; Leclerc C
Vaccine; 2006 Apr; 24(17):3490-9. PubMed ID: 16524647
[TBL] [Abstract][Full Text] [Related]
7. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.
Ensoli B; Cafaro A
J Biol Regul Homeost Agents; 2000; 14(1):22-6. PubMed ID: 10763887
[TBL] [Abstract][Full Text] [Related]
8. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
[TBL] [Abstract][Full Text] [Related]
10. Some recent results on HIV pathogenesis with implications for therapy and vaccines.
Gallo RC; Garzino-Demo A
Cell Mol Biol (Noisy-le-grand); 2001 Nov; 47(7):1101-4. PubMed ID: 11838957
[TBL] [Abstract][Full Text] [Related]
11. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.
Buttò S; Fiorelli V; Tripiciano A; Ruiz-Alvarez MJ; Scoglio A; Ensoli F; Ciccozzi M; Collacchi B; Sabbatucci M; Cafaro A; Guzmán CA; Borsetti A; Caputo A; Vardas E; Colvin M; Lukwiya M; Rezza G; Ensoli B;
J Infect Dis; 2003 Oct; 188(8):1171-80. PubMed ID: 14551888
[TBL] [Abstract][Full Text] [Related]
12. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo.
Re MC; Furlini G; Vignoli M; Ramazzotti E; Roderigo G; De Rosa V; Zauli G; Lolli S; Capitani S; La Placa M
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(4):408-16. PubMed ID: 7583436
[TBL] [Abstract][Full Text] [Related]
13. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides.
Belliard G; Hurtrel B; Moreau E; Lafont BA; Monceaux V; Roques B; Desgranges C; Aubertin AM; Le Grand R; Muller S
Vaccine; 2005 Feb; 23(11):1399-407. PubMed ID: 15661389
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.
Ensoli B; Fiorelli V; Ensoli F; Lazzarin A; Visintini R; Narciso P; Di Carlo A; Monini P; Magnani M; Garaci E
AIDS; 2008 Oct; 22(16):2207-9. PubMed ID: 18832884
[TBL] [Abstract][Full Text] [Related]
15. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters.
Rezza G; Fiorelli V; Dorrucci M; Ciccozzi M; Tripiciano A; Scoglio A; Collacchi B; Ruiz-Alvarez M; Giannetto C; Caputo A; Tomasoni L; Castelli F; Sciandra M; Sinicco A; Ensoli F; Buttò S; Ensoli B
J Infect Dis; 2005 Apr; 191(8):1321-4. PubMed ID: 15776379
[TBL] [Abstract][Full Text] [Related]
16. Serum HHV8 DNA and Tat antibodies in Kaposi's sarcoma patients with and without HIV-1 infection.
Massambu C; Pyakurel P; Kaaya E; Enbom M; Urassa W; Demirhan I; Loewer J; Linde A; Chandra A; Heiden T; Doerr HW; Chandra P; Biberfeld P
Anticancer Res; 2003; 23(3B):2389-95. PubMed ID: 12894519
[TBL] [Abstract][Full Text] [Related]
17. Infection and replication of Tat- human immunodeficiency viruses: genetic analyses of LTR and tat mutations in primary and long-term human lymphoid cells.
Chang LJ; Zhang C
Virology; 1995 Aug; 211(1):157-69. PubMed ID: 7645208
[TBL] [Abstract][Full Text] [Related]
18. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma.
Demirhan I; Chandra A; Mueller F; Mueller H; Biberfeld P; Hasselmayer O; Chandra P
J Hum Virol; 2000; 3(3):137-43. PubMed ID: 10881993
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus-1 Tat protein: immunological facets of a transcriptional activator.
Gupta S; Mitra D
Indian J Biochem Biophys; 2007 Oct; 44(5):269-75. PubMed ID: 18341200
[TBL] [Abstract][Full Text] [Related]
20. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides.
Moreau E; Belliard G; Partidos CD; Pradezinsky F; Le Buanec H; Muller S; Desgranges C
J Gen Virol; 2004 Oct; 85(Pt 10):2893-2901. PubMed ID: 15448351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
